<DOC>
	<DOCNO>NCT00030095</DOCNO>
	<brief_summary>RATIONALE : 2-Methoxyestradiol may stop growth cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness 2-methoxyestradiol treating patient advance solid tumor .</brief_summary>
	<brief_title>2-Methoxyestradiol Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose 2-methoxyestradiol patient advance solid tumor . - Determine side effect profile drug patient . - Determine pharmacokinetic profile drug patient . - Determine change positron-emission tomography scan patient treated drug . - Determine change apotosis patient treat drug . OUTLINE : This dose-escalation study . Patients receive oral 2-methoxyestradiol ( 2ME2 ) day 1 follow 2 day evaluation . Patients receive oral 2ME2 every 12 hour . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 2ME2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow day 30 . PROJECTED ACCRUAL : A total 30 patient accrue study within 1 year .</detailed_description>
	<mesh_term>2-methoxyestradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Metastatic unresectable disease standard curative treatment exist longer effective Clinically progressive disease document follow : New area malignant disease Progression softtissue metastasis At least 1 new metastatic deposit technetium Tc 99m bone scintigraphy Increases prostatespecific antigen Lesions accessible serial biopsy No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No concurrent uncontrolled illness No ongoing active infection No prior allergic reaction compound similar chemical biological composition 2methoxyestradiol No psychiatric illness social situation would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month , , 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin , nitrosoureas , carboplatin ) No concurrent chemotherapy cancer Endocrine therapy : Luteinizinghormone releasinghormone agonist therapy must continue patient prostate cancer except prior orchiectomy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy cancer Surgery : See Endocrine therapy Other : Recovered prior therapy No concurrent therapy cancer No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>